📊 RMTG Key Takeaways
Is RMTG a Good Investment? Thesis Analysis
RMTG exhibits severe financial distress with negative stockholders' equity of -$30.1M and a critical liquidity crisis (current ratio 0.09x), indicating technical insolvency. Despite 70.4% revenue growth and healthy 57.6% gross margins, the company generates a -$6.4M net loss on $3.5M revenue with negative operating cash flow of -$744.7K. Without immediate capital restructuring or substantial funding, the company lacks runway to continue operations.
Why Buy RMTG? Key Strengths
- 70.4% year-over-year revenue growth demonstrates strong market demand
- 57.6% gross margin indicates viable product and pricing power
- Net loss improved 43.3% YoY showing operational trajectory enhancement
RMTG Investment Risks to Consider
- Negative stockholders' equity of -$30.1M indicates technical insolvency with liabilities exceeding assets
- Critical liquidity crisis with current ratio 0.09x leaves minimal ability to meet short-term obligations
- Negative operating cash flow of -$744.7K with only $1.2M cash runway insufficient for operational sustainability
Key Metrics to Watch
- Monthly cash burn rate and remaining runway before capital depletion
- Operating expense reduction progress and path to positive cash flow
- Capital raise announcements or debt restructuring events
RMTG Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RMTG Profitability Ratios
RMTG vs Consumer Sector
How Regenerative Medical Technology Group Inc. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RMTG Overvalued or Undervalued?
Based on fundamental analysis, Regenerative Medical Technology Group Inc. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RMTG Balance Sheet & Liquidity
RMTG 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Regenerative Medical Technology Group Inc.'s revenue has grown significantly by 7,357% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.79 indicates the company is currently unprofitable.
RMTG Growth Metrics (YoY)
RMTG Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $1.6M | -$2.0M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RMTG Capital Allocation
RMTG SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Regenerative Medical Technology Group Inc. (CIK: 0001760026)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RMTG
What is the AI rating for RMTG?
Regenerative Medical Technology Group Inc. (RMTG) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RMTG's key strengths?
Claude: 70.4% year-over-year revenue growth demonstrates strong market demand. 57.6% gross margin indicates viable product and pricing power.
What are the risks of investing in RMTG?
Claude: Negative stockholders' equity of -$30.1M indicates technical insolvency with liabilities exceeding assets. Critical liquidity crisis with current ratio 0.09x leaves minimal ability to meet short-term obligations.
What is RMTG's revenue and growth?
Regenerative Medical Technology Group Inc. reported revenue of $3.5M.
Does RMTG pay dividends?
Regenerative Medical Technology Group Inc. does not currently pay dividends.
Where can I find RMTG SEC filings?
Official SEC filings for Regenerative Medical Technology Group Inc. (CIK: 0001760026) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RMTG's EPS?
Regenerative Medical Technology Group Inc. has a diluted EPS of $-0.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RMTG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Regenerative Medical Technology Group Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RMTG stock overvalued or undervalued?
Valuation metrics for RMTG: ROE of N/A (sector avg: 18%), net margin of -181.9% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy RMTG stock in 2026?
Our dual AI analysis gives Regenerative Medical Technology Group Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RMTG's free cash flow?
Regenerative Medical Technology Group Inc.'s operating cash flow is $-744.7K, with capital expenditures of $335.4K. FCF margin is -30.6%.
How does RMTG compare to other Consumer stocks?
Vs Consumer sector averages: Net margin -181.9% (avg: 8%), ROE N/A (avg: 18%), current ratio 0.09 (avg: 1.5).